Sanofi-Aventis Merger Clears FTC; Estorra Rights To Be Divested
Executive Summary
Sanofi and Aventis will begin integrating management and operations following the Federal Trade Commission's July 28 approval of the merger of the two companies
You may also be interested in...
Ketek Is Emerging As Lens For Wider Hill Scrutiny Of Clinical Trial Integrity
The House Energy and Commerce Committee's inquiries into Sanofi-Aventis' Ketek could be a jumping-off point for a wide-ranging congressional look into the integrity of clinical trials and oversight of companies involved in those trials
Ketek Is Emerging As Lens For Wider Hill Scrutiny Of Clinical Trial Integrity
The House Energy and Commerce Committee's inquiries into Sanofi-Aventis' Ketek could be a jumping-off point for a wide-ranging congressional look into the integrity of clinical trials and oversight of companies involved in those trials
Sanofi-Aventis is born
Sanofi-Synthelabo and Aventis merger closes Aug. 20, creating third largest pharma company, Sanofi-Aventis, with Sanofi obtaining control of 95.5% of Aventis' share capital. Completion of the merger follows required divestiture of Estorra (1"The Pink Sheet" Aug. 16, 2004, p. 34)...